FIELD: nanotechnology; cancer therapy.
SUBSTANCE: composition for the treatment of carcinomas in a human, using boron-neutron capture therapy, is claimed, which includes a neutron capture agent and nanomaterial of biodegradable periodic mesoporous organosilica (hereinafter – BPMO) compounds. BPMO is modified by introduction of a disulfide bond, a tetrasulfide bond, or a protease-sensitive bond, and the surface of BPMO is modified using phosphonate. The invention also relates to a method for introduction of the neutron capture agent into nanomaterial of BPMO, which includes synthesis of BPMO, using a method for sol-gel synthesis, modification of the surface of BPMO, and loading of BPMO with the modified surface with the neutron capture agent. A method for neutron capture therapy in the treatment of cancer, using a composition, as well as kits for use in therapeutic purposes for the treatment of carcinomas are also claimed.
EFFECT: group of inventions provides new and improved methods for the treatment of cancer and immunological disorders.
18 cl, 6 dwg, 7 ex
Title | Year | Author | Number |
---|---|---|---|
BORYLATED AMINO ACID COMPOSITIONS FOR USE IN BORON NEUTRON CAPTURE THERAPY AND METHODS THEREOF | 2020 |
|
RU2818817C2 |
COMPOSITION FOR ACTIVATED NANOPARTICLES PLGA, LOADED WITH ACTIVE SUBSTANCE FOR TARGETED NANOTHERAPY OF CANCER | 2008 |
|
RU2473331C2 |
MODULAR PARTICLES FOR IMMUNOTHERAPY | 2014 |
|
RU2672055C2 |
BORTEZOMIB BASED DELIVERY SYSTEM | 2016 |
|
RU2727156C2 |
NANOPARTICLE, CONTAINING RAPAMYCIN AND ALBUMIN AS ANTI-CANCER AGENT | 2008 |
|
RU2483714C2 |
RADIOTHERAPEUTIC PARTICLES AND SUSPENSIONS | 2016 |
|
RU2770073C2 |
NANOPARTICLE, CONTAINING RAPAMYCIN AND ALBUMIN AS ANTICANCER AGENT | 2013 |
|
RU2678448C2 |
BIODEGRADABLE METAL IMPLANT FOR LOCAL IMMUNOTHERAPY OF PATIENTS WITH SOLID TUMORS | 2021 |
|
RU2780927C1 |
COMBINATIONS AND METHODS FOR ADMINISTRATION OF THERAPEUTIC AGENTS AND COMBINATION THERAPY | 2013 |
|
RU2673805C2 |
ANTIBODIES POLYPEPTIDES AND USE THEREOF | 2014 |
|
RU2687163C1 |
Authors
Dates
2022-10-04—Published
2019-05-31—Filed